Paper by Dr Lane titled Licensing Arrangements for Heat-Treated Factor VIII and Factor IX Factor VIII intermediate purity, code HL(H), will be used as a stop-gap pending satisfactory clinical information on heat-treated product VIII-Y, which has been released to selected Haemophilia Centres for trial to determine safety and clinical efficacy. Further discusses testing and anticipated clinical trial of Factor IX, heat treated factor IX.